Macquarie Group
SMMT icon

Macquarie Group’s Summit Therapeutics SMMT Stock Holding History

Macquarie Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,705
Closed -$143K – 1693
2025
Q2 		$143K Sell
6,705
-103,008
-94% -$2.35M ﹤0.01% 1558
2025
Q1 		$2.12M Buy
109,713
+23,960
+28% +$481K ﹤0.01% 1203
2024
Q4 		$1.53M Buy
+85,753
New +$1.66M ﹤0.01% 1270
2024
Q3 		– Sell
-1,274
Closed -$9.94K – 1877
2024
Q2 		$9.94K Buy
+1,274
New +$6.88K ﹤0.01% 1659

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return

Macquarie Group's SMMT Position: Q3 2025 in Review

Macquarie Group sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 6,705 shares — an estimated $143K sold.

Macquarie Group first reported a position in SMMT in Q2 2024 and held it in 4 quarters. The position peaked at $2.12M in Q1 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Macquarie Group reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Macquarie Group sold 6,705 Summit Therapeutics shares in Q3 2025, an estimated $143K.
  • Macquarie Group first reported a position in Summit Therapeutics in Q2 2024 and held it in 4 quarters.
  • Macquarie Group's Summit Therapeutics position peaked at $2.12M in Q1 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Macquarie Group's 13F filing for Q3 2025, filed 13 Nov 2025.